HematologyNovartis
Novartis Reports Phase 3 Results for Iptacopan in Paroxysmal Nocturnal Hemoglobinuria
BMI
Biotechnology Media Insights
Editorial Team · November 15, 2023
Novartis announces Phase 3 APPLY-PNH trial results showing iptacopan significantly improves hemoglobin in PNH patients with residual anemia.
Novartis today announced results from the Phase 3 APPLY-PNH trial evaluating iptacopan in patients with paroxysmal nocturnal hemoglobinuria who had residual anemia despite anti-C5 therapy. The trial met its primary endpoint, demonstrating a significant increase in hemoglobin levels with iptacopan compared to anti-C5 therapy alone.
BMI
Biotechnology Media Insights
Published by Biotechnology Media Insights — your trusted source for pharmaceutical, biotech, and life sciences news.